Kornimate/medical-research-clean huggingface dataset:
efficacy of seprapack sinus dressing versus no dressing in the prevention of intranasal adhesions following sinus surgery

Conditions: Chronic Sinusitis

Summary: the purpose of this study is to investigate if the space occupying effect of seprapack will lead to a reduction in post operative adhesions and more healing of the sinus cavity when compared to the use of no packing material.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * requiring bilateral endoscopic ethmoidectomy (anterior or posterior) * intact middle turbinates * willing to return for all follow-up visits * signed written informed consent exclusion criteria: * patients with craniofacial abnormalities (e.g. cleft palate) * patients without intact middle turbinates * patients on long-term oral steroids or other chemotherapeutic agents that might delay healing. short-term pulse steroid therapy and topical steroids are acceptable * patients with inflammatory conditions, other than chronic sinusitis or nasal polyposis, including but not limited to sarcoidosis, rhinitis, ozena, wegner's granulomatosis, nasal malignancy, recreational drug abuse * patients with cystic fibrosis * women that are pregnant or women of childbearing age potential who are not practicing an acceptable method of birth control * patients with bleeding disorders or who are receiving anticoagulants * patients that may require a lothrop procedure

Keywords: sinus
case-control study of mesh-infection after a size tailored hernia repair with c-qur v-patch

Conditions: Ventral Hernia; Umbilical Hernia; Epigastric Hernia; Trocar-site Hernia

Summary: ventral hernias, such as umbilical, epigastric and trocar-site hernias, are best repaired with abdominal wall reinforcement by mesh implantation. mesh-devices using a dual-sided mesh technology have been developed for the specific indication of small ventral hernias; this technique is very attractive because the mesh can be introduced through a nearly invisible scar in the umbilicus. the dual layer of the mesh inhibits the formation of adhesions of the viscera to the mesh so, if wanted, it can be positioned in a intraperitoneal position. no literature is available on the adequate size of mesh needed to repair a hernia defect of an umbilical or epigastric hernia. very small hernias are now often enlarged for repair with a large mesh device. small hernias might benefit of repair with a small mesh device so no enlargement of the defect is necessary larger hernias might benefit from a larger mesh size to have more overlap of the mesh beyond the hernia defect. the situp-trial was a prospective cohort study who was designed to explore the efficacy of c-qur v-patch of different sizes for the different sizes of hernia defects. the study was stopped prematurely because of the perception of an unacceptably high rate of mesh infection. this new study will retrospectively examine the incidence of mesh infection in all ventral hernias repaired with a c-qur v-patch. collection of patient data was done using the eura-hs registry.


Eligibility criteria:
inclusion criteria: all adult patients that are planned for surgical repair of a umbilical, epigastric or trocar-site hernia will be considered to enter the study. exclusion criteria: patients refusing to participate at the follow up visits pregnancy age \< 18 years life expectancy less than 12 months emergency operations liver cirrhosis or ascites cancer patients concomitant surgery other than hernia repair

Keywords: primary ventral hernia repair with mesh umbilical hernia repair epigastric hernia repair c-qur v-patch size tailored repair preperitoneal repair abdominal hernia dual sided mesh trocar-site hernia
tshβx1 and d2 thr92ala in pregnancy

Conditions: Pregnancy Related; Hypothyroidism; Hyperthyroidism

Summary: thyroid diseases are pathologies that frequently affect pregnant women causing serious complications. this current research aims to find out whether the expression of tshβx1 splice variant and d2 thr92ala polymorphism in the dio2 gene are associated with thyroid disease in mexican pregnant women.

deiodinase 2 (dio2) is a selenoenzyme responsible for the deiodination of t4 to t3, which makes it crucial for the proper functioning of thyroid hormones. polymorphisms of dio2 alters the enzymatic function. in addition, the ala92ala genotype was reported to be related with a reduction in the placental activity of d2, which could worsen gestational complications. in the other hand, the tshβ gene (nc_000001.11) located on chromosome 1 at position 38p12, codes for the beta unit of the thyroid stimulating hormone (tsh). it is admitted that genetic variants can show a different spectrum of actions. this was a clinical, comparative, prospective and transversal study. pregnant women aged 18-44 years old, were invited to identify it they had a dio2 polymorphism or the tshβx1 splice variant.

Eligibility criteria:
inclusion criteria: * pregnant women attended at the "mónica pretelini sáenz" maternal-perinatal hospital (hmpmps), health institute of the state of mexico (isem), toluca, mexico. exclusion criteria: * patients with chronic diseases other than hyper or hypothyroidism. * patients that required attention in the obstetric intensive care unit.

Keywords: hyperthyroidism polymorphism tshβx1 d2 thr92ala hypothyroidism
coached or non-coached weight loss intervention

Conditions: Obesity; Behavior, Health; Behavior, Eating; Weight Loss; Overweight and Obesity; Self Efficacy

Summary: to evaluate the effect of one-on-one coaching in the noom healthy weight program, a digital behavior change, weight loss intervention, compared to the same program with no coaching, as well as influential factors.


Eligibility criteria:
inclusion criteria: * able to understand and provide informed consent * 18-65 years old * self-report of good health (physical and mental) * not diagnosed with diabetes * overweight or obesity (bmi ≥ 27) * able to meet our criteria of adherence to the program (at least 1 engagement per week on one of the following: logged exercise, logged meals, steps, weigh-ins, coach messages, read articles, and days with at least one weigh-in.) for females * not 6 months postpartum * not planning to become pregnant in the next 5 months. exclusion criteria: * inability or unwillingness of a participant to give written informed consent * currently pregnant or ≤ 6 months postpartum * presence of a condition or abnormality that in the opinion of the investigator would compromise the quality of the data e.g., evidence of an eating disorder, major chronic condition
comparison of the efficacy and safety of risperidone versus risperidone plus low dose of haloperidol in the treatment of schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to compare the efficacy and safety of risperidone and risperidone plus low dose of haloperidol in the acutely schizophrenic patients.

antipsychotic monotherapy is recognized as the treatment of choice for patients with schizophrenia. surveys have shown that antipsychotic drug combinations are frequently prescribed, yet few clinical studies have examined this practice. risperidone, an atypical antipsychotics, has low incidence of extrapyramidal symptom (eps) but with high cost compared to haloperidol. it has been reported that a relatively low daily dose of haloperidol at which individual patients develop slightly increase in eps and has neurocognitive benefits as risperidone. the objective of the study is to compare the efficacy and safety of the fixed-dosed risperidone and risperidone combined with haloperidol in the treatment of acute psychotic exacerbations of schizophrenia.in this 6-week, double-blind, fixed-dose study, patients with schizophrenic disorder (dsm-iv diagnosis) are randomly assigned to risperidone (4 mg/d) or risperidone (2 mg/d) plus haloperidol (2 mg/d). the hypothesis is that the two treatment groups have the similar efficacy and safety, but different cost. the primary efficacy measure is change from baseline in positive and negative syndrome scale (panss) total scores; secondary outcomes include clinical global impression-change (cgi-c), the calgary depression scale for schizophrenics (cdss), subject-reported outcomes via the short form-36 (sf-36), auditory evoked potentials (aeps), and cognitive and social functioning. safety assessments include the change from baseline on simpson-angus rating scale (sas), abnormal involuntary movement scale (aims), barnes akathisia scale (bas), and uku side-effects rating scale (uku), and the change from baseline in prolactin levels, body weight, ac glucose level, lipid panel (cholesterol, high density lipid protein \[hdl\], low density lipid protein \[ldl\], and triglyceride \[tg\])

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia * clinical global impression large than 3 * written informed consent exclusion criteria: * comorbid of substance abuse/dependence * present or history of tardive dyskinesis or neuroleptic malignant syndromes * severe physical problems * pregnant or lactating women
long term extension study to assess the safety and efficacy of filgotinib in adults with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the parent studies of filgotinib in rheumatoid arthritis (ra).


Eligibility criteria:
key inclusion criteria: * males or females who may benefit from filgotinib as judged by the investigator and who completed a gilead sponsored filgotinib parent study for ra as outlined below: * have completed gs-us-417-0301, gs-us-417-0302 or gs-us-417-0303 on study drug * or * have completed gs-us-417-0302 on standard of care therapy due to ra non-responder status * females of childbearing potential must have a negative pregnancy test prior to first dose of study drug in the long term extension (lte) * females of childbearing potential who engage in heterosexual intercourse must agree to protocol-approved methods of contraception key exclusion criteria: * diagnosis of an autoimmune or inflammatory joint disease other than ra, which would put the participant at risk by participating in the study or would interfere with study assessments/data interpretation, per judgment of the investigator * known hypersensitivity to the study drug or its excipients * any medical condition which would put the participant at risk by participating in the study or would interfere with study assessments/data interpretation, per judgment of the investigator note: other protocol defined inclusion/ exclusion criteria may apply.
evaluation of intraocular pressure lowering-effect of xalacom in patients with poag or oh.

Conditions: Glaucoma; Ocular Hypertension

Summary: this study is designed as an open label evaluation of the efficacy of latanoprost and timolol fixed combination (xalacom) after 6 month of treatment. eligible patients may be enrolled at the baseline visit. all current ocular hypotensive therapy must be discontinued at this time. on baseline day, patients eligible for the study will receive xalacom which is to be instilled in the morning.


Eligibility criteria:
inclusion criteria: * diagnosis of glaucoma (primary open angle, pigmentary, exfoliative) or ocular hypertension (iop \>= 21 mmhg). * visual acuity \>= 20/200. exclusion criteria: * closed/barely open anterior chamber angle or history of acute angle closure glaucoma. * hystory of alt within 3 months prior to the baseline visit. * history of any ocular filtering surgical intervention. * ocular surgery or inflammation/infection within 3 months prior to the baseline visit.
relationship between hemodynamic changes and cardiopulmonary fitness in type 2 diabetes mellitus patients

Conditions: Diabetes Mellitus Type 2 (T2DM)

Summary: diabetes mellitus being metabolic disorder, chronic in nature, is characterized by high levels of glucose in our blood, which often lead to organ dysfunction. approximately 10.5 % of adult (20-79 years) have diabetes according to international diabetes federation. cardiorespiratory fitness (crf) is the capability of our cardiopulmonary system to make oxygen available to our skeletal muscles during physical activities for prolonged time, and is known to be decreased with diabetes. hemodynamic parameters are correlated with various cardiovascular disorders but little evidence of hemodynamic changes in diabetes patients is present and more studies must be done. this study aims to establish the link between hemodynamic changes and cardiopulmonary fitness in t2dm patients, which could inform clinical practices and interventions to improve management, reduce cardiovascular risks, and enhance the quality of life for these patients.

diabetes mellitus being metabolic disorder, chronic in nature, is characterized by high levels of glucose in our blood, which often lead to organ dysfunction.\[1\] diabetes statistics highlight the increasing worldwide impact on individuals, families and nations. approximately 10.5 % of adult (20-79 years) have diabetes according to international diabetes federation. \[2\] cardiorespiratory fitness (crf) is the capability of our cardiopulmonary system to make oxygen available to our skeletal muscles during physical activities for prolonged time. \[3\] diabetes and cardiorespiratory fitness are inter related. according to a 2023 studies on cardiorespiratory fitness in individuals with t2dm, it was found that t2dm was associated with decreased cardiorespiratory fitness. hemodynamic characteristics have been linked to diseases like stroke,, hypertension, and vascular stenosis. only a few modest studies have investigated the relationship between hemodynamics and diabetes mellitus (dm). the evidence for a link between hemodynamic alterations and crf in type 2 diabetic individuals needs to be demonstrated. the study aimed to identify the relationship between hemodynamic changes and crf in type 2 diabetic patients; the findings will help us form inform clinical practices and intervention strategies, ultimately leading to better t2dm management, lowering the risk of cardiovascular complications, and improving t2dm patients' quality of life and longevity.

Eligibility criteria:
inclusion criteria: * subjects who agreed to sign the informed consent form. * subject with an age group 30-50yrs. * female and male. * controlled type 2 diabetes mellitus patients. exclusion criteria: * patient performing any exercise. * cardiovascular diseases. * patients with cerebrovascular diseases. * patients with peripheral artery diseases. * patients with pulmonary dysfunction.

Keywords: diabetes mellitus hemodynamic changes
blister packaging medication to increase treatment adherence and clinical response

Conditions: Medication Adherence; Accidental Overdose; Deliberate Overdose; Suicide, Attempted

Summary: this quantitative, interview-based study will determine if increased prescription medication adherence via blister pack administration will reduce suicide related behavior among the high risk population of patients discharged from a psychiatric inpatient unit. the aims of the project are to determine whether blister packaging medication significantly increases treatment adherence and if blister packaging significantly decreases intentional self-poisoning behavior (i.e., suicide attempts and completions). by tracking former psychiatric inpatients for 12 months post-discharge and obtaining monthly medication adherence ratings, we will determine if blister packaging (bp) medications leads to better adherence than dispensing as usual (dua). the psychiatric patients we will be recruiting have been diagnosed with, major affective disorder, bipolar affective disorder, post-traumatic stress disorder, or schizophrenia (or any combination of these diagnoses). by tracking former psychiatric patients for 12 months post-discharge and obtaining monthly reports (self-report and medical record review) of suicide-related behaviors, we will determine if patients in the bp condition have less intentional self-poisoning behavior than those in the dau condition.


Eligibility criteria:
inclusion criteria: * age 18 or older * diagnosed with major affective disorder, * bipolar affective disorder, * post-traumatic stress disorder, or * schizophrenia (or any combination of these diagnoses) * under voluntary status at some point during admission * currently prescribed medications * deemed capable of managing their own medications after discharge * not currently active duty in any branch of the military * able to correctly answer questions verifying they understand the consent form * english-speaking exclusion criteria: * under the age of 18 * not under voluntary status at some point during admission * not currently prescribed medications * not able to manage their own medications after discharge * non-english-speaking * currently active duty in any branch of the military * inability to correctly answer questions indicating comprehension of information on the consent form

Keywords: medication adherence accidental overdose deliberate overdose suicide, attempted
comparison between point of care device and venous blood international normalized ratio measurements.

Conditions: Blood Coagulation Disorder

Summary: investigate the validity of hemosense system in pediatric patients on anticoagulation therapy.

over the last few decades there has been an increased use of warfarin in the pediatric population stemming from the use of mechanical heart valves and palliative surgical procedures requiring anticoagulation therapy. other patients with enzymatic deficiency within the coagulation cascade may develop thrombosis treated with anticoagulation, i.e. factor v leiden deficiency. prevention of poor outcome from thrombosis has required closer monitoring in the pediatric patient. in addition, absorption of warfarin in the pediatric population is highly variable and depends on the child's age, weight, diet, and concurrent use of other medications (desai, 2000). this makes achieving anticoagulation very difficult. "because of the intrinsic differences in the coagulation systems in children and adults, guidelines for antithrombotic therapy in adults cannot be extrapolated to pediatrics" (desai, 2000). therefore, pediatric patients on anticoagulation therapy require frequent lab work to monitor their prothrombin time and international ratios (pt/inr). there are a number of barriers to care when discussing anticoagulation therapy for pediatric patients. frequent venous blood draws represent a painful procedure that elicit anxiety and fear which leads to noncompliance. in addition, children are more difficult to obtain blood samples because of smaller vessels, patient movement during procedure, and the volume of blood that is required for the test. other barriers include the time delay from when the patient has the lab work drawn, to when the result get to the provider for any patient care decisions to be made. there are a number of point of care devices available for near-patient testing of the pt/inr's that requires only a finger stick. these monitors have been validated against standardized laboratory testing, in order for the monitor to be certified by the fda. similar studies to validate finger stick methods in pediatric patients have not been completed. the aim of this project is to validate the accuracy of hemosense, a point of care device, to venous blood pt/inr level in the pediatric population.

Eligibility criteria:
inclusion criteria: - all pediatric patient requiring warfarin therapy. exclusion criteria: 1. subjects older then 18 year of age. 2. pregnant subjects.

Keywords: blood coagulation pt/inr warfarin mechanical valve
addressing financial hardship in adolescent and young adult cancer survivors

Conditions: Hematopoietic Neoplasm; Malignant Solid Neoplasm; Lymphatic System Neoplasm

Summary: this study seeks to develop, test, and revise an intervention designed to address financial hardship (finfit) among adolescent and young adult (aya) cancer survivors.

primary objective: i. to synthesize chat and lift to create finfit, an intervention to address the unique, multilevel determinants of financial hardship among ayas treated in community oncology practices. outline: this is an observational study. step 1: chat participants complete an in-depth interview on study. step 2: lift participants complete a focus group or an interview on study. step 3: participants from steps 1 and 2 complete member-checking processes on study.

Eligibility criteria:
inclusion criteria: - adults (ages 18 years of age or older) with perspectives on chat, lift, finfit's proposed forms, and those from any community-based practices that were originally part of chat or lift administration are eligible for inclusion in aim 1 interviews. exclusion criteria: - those not involved in any of the preliminary programs, not familiar with the proposed forms of finfit, or not involved in the proposed implementation sites will not be eligible for participation.
influence of spinal stimulation frequency on spasticity, motor control, and pain after spinal cord injury

Conditions: Spinal Cord Injuries

Summary: the goal of this study is to identify the effect of different types of noninvasive spinal stimulation on spasticity (involuntary muscle activity), muscle strength, and pain in people with spinal cord injury. the spinal stimulation consists of electrical stimulation applied through one electrode over the skin of the lower back and two electrodes over the stomach. testing will include participating in measurements before the intervention, during intervention, and immediately after the intervention. this study requires participants to come into shepherd center 4 consecutive days a week for 2-3 hours per day across 2-3 weeks.

transcutaneous spinal stimulation (tss) is a noninvasive electrical stimulation that is applied over the skin of the low back and stomach. in prior research studies, tss has reduced spasticity without the negative side effects of drug therapies. although research in tss is growing, the best dosage of tss remains unknown. the investigators want to further advance the effects of tss by comparing three different frequencies. frequency is the number of electrical pulses that are delivered over a period of time. frequency can affect the activation of nerves and therefore affect the outcome of tss. participation in this study includes testing of the participants' spasticity, strength, and pain before and after 30 minutes of tss.

Eligibility criteria:
inclusion criteria: * participants must agree to allow use of health information. * participants should be 16 years old or older. * participants must have had a spinal cord injury (sci) of any severity (ais a, b, c, or d) that happened at least 3 months ago. * objectively measurable spasticity in your legs. * participants must inform the investigators if there is a change in medications during the study. * participants must be able to follow instructions. * participants must be able to communicate if pain or discomfort is experienced. exclusion criteria: * people with spinal issues that are getting worse, such as degenerative or progressive vascular disorders. * people neurological problems other than sci. * people with an injury level is below t12. * people with heart issues, such as atrial fibrillation. * people with bone or joint problems that would make it hard to follow the study plan. * women who are pregnant. * people with implanted stimulators (like a baclofen pump, spinal stimulator, heart defibrillator, or diaphragmatic pacemaker) * people with infection. * people with skin that is broken. * people who have or had certain types of cancer. * people who have had long-lasting spasticity treatment (like botox or selective dorsal rhizotomy).